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Abstract 
Generation of selective anti-GPCR antibodies is a challenging pursuit, and the anti-
histamine receptor antibodies are no exception. Furthermore, producing isoform-
selective antibodies is even more of a challenge. The first anti-histamine H3 receptor 
(H3) antibodies were developed in 2001 and validated in 2007. The first two antibodies 
were raised against human H3 receptor sequences common to most human and rodent 
isoforms. This chapter describes how a panel of anti-hH3 receptor isoform specific 
antibodies have been generated, characterised and validated for selectivity (individual 
rH3R and hH3R isoform transient expression in HEK293 cells, isoform peptide blockade 
and the use of H3R KO mice), and utility for a range of immunobiochemical techniques 
(immunoblotting, immunohistochemical and immunofluorescence techniques).  
 
Introduction 
Due to lower than expected homology with histamine receptors H1 and H2, the H3 
receptor was not cloned until 1999 (1) more than a decade after it was first described 
by seminal studies in France (2) It was discovered as part of an effort to identify orphan 
GPCRs. Lovenberg and colleagues identified a partial clone (GPCR97) that had 
significant homology to a range of biogenic amine receptors. The GPCR97 clone was 
used to probe a human thalamus library, which resulted in the isolation of a full-length 
clone encoding a putative G protein- coupled receptor. Homology analysis showed the 
highest similarity to M2 muscarinic acetylcholine receptors and overall low homology to 
all other biogenic amine receptors. Subsequent analysis revealed a pharmacological 
profile practically indistinguishable from that for the histamine H3 receptor. In two 
analyses of the human gene (3,4) a 1063 base pair (bp) intron beginning 250 
nucleotides downstream of the start codon (corresponding to aa 84) and another 1564 
bp intron at position 417 (corresponding to aa 139) suggests a gene with three exons 
and two introns. By contrast Cogé (5) has put forward a gene having a minimum of 
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four exons and three introns. In their analysis the coding region is interrupted by introns 
of 1062, 1565 and 240 bp. A further exon may result in an additional 8 amino acids at 
the C-terminus, leading to a protein of 453 aa. The result of these diverse exon/intron 
junctions is the possibility of alternative splicing to generate multiple splice variants 
which may potentially lead to several receptor isoforms. 
The cloning of the H3 receptor initiated a new era in histamine research. The existence 
of multiple H3 receptor isoforms could contribute to the pharmacological heterogeneity 
in H3 receptors, within and across species, which has long been recognised, but not 
understood. In all species tested so far the full length H3 receptor encodes a polypeptide 
of 445 amino acids (predicted polypeptide Mr 47,000). Shorter isoforms with deletions 
predominantly in the third intracellular loop domain have also been identified (predicted 
polypeptide Mr range 20,000-45,000). While the full length clone is found in most 
abundance in the CNS in all species studied so far, there is regional variation in the 
distribution of the mRNAs encoding the different isoforms (5); this has given rise to 
speculation that H3 heterogeneity could underlie different activities and functions of H3 
receptors in specific tissues (6). 
 
The evidence for heterogeneity in anatomical distribution was based initially on the 
distribution pattern of mRNA coding for the various isoforms. Note that these splicing 
events yield potentially different protein sequences in rodents and human H3R 
orthologs. In order to define the importance of human and rodent H3 receptor 
heterogeneity, specific immunological probes are required.  
Generation of selective anti-GPCR antibodies is a challenging pursuit, and the 
histamine receptors are no exception. Furthermore, producing isoform-selective 
antibodies is even more testing. The first anti-histamine H3 receptor (H3) antibodies 
were developed in 2001 and validated using KO Mice in 2007 (7,8). The first two 
antibodies were raised against human H3 receptor sequences common to most human 
and rodent isoforms: anti-hH3 (346-358) and anti-hH3 (175-187), respectively. They both 
detected two specific immunoreactive protein species (Mr 68,000 and 93,000) which 
were suppressed by prior incubation with their respective peptide antigens, in many 
adult rat and mouse brain regions. These protein species are most likely derived from 
dimeric and/or glycosylation variants of the receptor.  
 
In an attempt to generate an antibody specific to the rat H3C (397) isoform a peptide 
sequence was chosen which spanned the deletion within the third intracellular loop rat 
isoform sequences, and should therefore be unique to this isoform (Figure 1). However, 
when tested against three of the major human and rat isoforms heterologously 
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expressed in HEK 293 cells namely hH3 (445), hH3 (365) and hH3 (329); rH3A (445), rH3B (413) 
and rH3C (397), the antibody was found to be selective for both the full length human and 
rat isoforms (hH3 (445) and rH3A (445)) as well as the expected rH3C (397) isoform. Using this 
same strategy antibodies specific for three of the other major human H3R isoforms: 415, 
365, and 329 ∆I3 (see Fig 2 human isoform sequences), were also sought. Finally a 
peptide sequence unique to the heavily truncated human H3 220 was selected ((9), 
Isoform 5). Human H3 (220) has a 170-306 deletion plus a frame shift and a novel stop 
codon, so that the C terminus is unique to this isoform. Therefore, the last 10 amino 
acids of human H3 220 were selected as immunogen. 
 
Herein, methods are described for rationale selection and preparation of the peptides 
for immunization, the immunization procedure, antibody purification and the 
experiments performed to validate the individual antibody specificities. Results of 
immunohistochemical analysis using the human/rodent antibody in mouse brain slices 
from both wildtype (WT) and H3R -/- (H3R KO) mice (kind gift of Prof Tim Lovenberg, 
Johnson & Johnson) are also presented as exemplars. 
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Figure 1 Schematic showing how peptide sequences were selected in an attempt to 
produce isoform specific antibodies against the distinctly spliced third intracellular loop 
of the human H3R. Amino acid sequences were chosen that spanned either side of the 
splicing event so once the sequence was removed and the sequence at either side 
joined, the antibody generated would hopefully detect the sequence. The sequence 
selected was long enough so that the antibody was specific but not too long that the 
antibody would detect other closely related isoforms. 
 
Herein, the methods for preparing peptides for immunisation, the immunisation 
procedure, antibody purification and the experiments performed to check the individual 
antibody specificity are described.  
 
Peptide sequences chosen for each isoform: 
(A) Full length human H3R sequence.  
Peptide sequence used to generate anti-pan H3R antibody, blue 
1  merappdgpl nasgalagea aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61  adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts    
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121  safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg   
181  ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa    
241   gpepppeaqp spppppgcwg cwqkghgeam plhrygvgea avgaeageat lgggggggsv   
301  asptsssgss srgterprsl krgskpsass aslekrmkmv sqsftqrfrlsrdrkvaksl 
361  avivsifglc wapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421  raftkllcpq klkiqphssl ehcwk 
 
(B) Full length human H3R445 sequence.  
Peptide sequence used to generate anti-rH3RA/C and hH3R453/445antibody, blue 
1  merappdgpl nasgalagea aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61  adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts    
121  safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg   
181  ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa    
241   gpepppeaqp spppppgcwg cwqkghgeamplhrygvgea avgaeageat lgggggggsv   
301  asptsssgss srgterprsl krgskpsass aslekrmkmv sqsftqrfrl srdrkvaksl 
361  avivsifglc wapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421  raftkllcpq klkiqphssl ehcwk 
 
(C) Human sequence showing the H3R453 isoform (Addition of 8 amino acids in 
green). 
Peptide sequence used to generate: anti-human H3R445/453 antibody, blue 
1  merappdgpl nasgalagea aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61 adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts    
121  safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg   
181  ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa    
241    gpepppeaqp spppppgcwg cwqkghgeamplhrygvgea avgaeageat lgggggggsv   
301 asptsssgss srgterprsl krgskpsass aslekrmkmv sqsftqrfrl srdrkvaksl 
361  avivsifglc wapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421  raftkllcpq klkiqphssl ehcwkrrprprwrsa 
 
(D) Human sequence showing the H3R365 deletion / isoform 2 (deletion in red and 
bold). 
Peptide sequence used to generate: anti-human H3R365 peptide 1 antibody, blue 
1  merappdgpl nasgalagea aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61  adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts   
121  safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg   
181  ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa    
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241  gpepppeaqp spppppgcwg cwqkghgeam plhrygvgea avgaeageat   
lgggggggsv   
301 asptsssgss srgterprsl krgskpsass aslekrmkmv sqsftqrfrl srdrkvaksl 
361  avivsifglcwapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421  raftkllcpq klkiqphssl ehcwk 
 
(E) Human sequence showing the H3R365 deletion / isoform 2 (deletion in red and 
bold).  
Peptide sequence used generate: anti-human H3R365 peptide 2 antibody, blue 
1  merappdgpl nasgalagea aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61  adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts   
121 safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg   
181  ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa    
241  gpepppeaqp spppppgcwg cwqkghgeam plhrygvgea avgaeageat 
lgggggggsv   
301 asptsssgss srgterprsl krgskpsass aslekrmkmv sqsftqrfrl srdrkvaksl 
361  avivsifglcwapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421  raftkllcpq klkiqphssl ehcwk 
 
(F) Human sequence showing the H3R329 deletion / isoform 2 (deletion in red and 
bold). Peptide generated to the sequence at position 222-231 (anti-hH3R329 
antibody). 
Peptide sequence used to generate:anti-human H3R329 antibody, blue 
1  merappdgpl nasgalagea aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61  adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts    
121  safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpa ilsweylsgg   
181  ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa    
241 gpepppeaqp spppppgcwg cwqkghgeam plhrygvgea avgaeageat      
lgggggggsv   
301  asptsssgss srgterprsl krgskpsass aslekrmkmv sqsftqrfrl srdrkvaksl 
361  avivsifglc wapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421  raftkllcpq klkiqphssl ehcwk 
 
(G) Human sequence showing the H3R200 deletion / isoform 5 (deletion in red and 
bold). (Peptide sequence used to generate: anti-human H3R200 antibody, blue 
1  merappdgpl nasgalagea aaaggargfs aawtavlaal mallivatvl gnalvmlafv 
61  adsslrtqnn ffllnlaisd flvgafcipl yvpyvltgrw tfgrglcklw lvvdyllcts    
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121  safnivlisy drflsvtrav syraqqgdtr ravrkmllvw vlafllygpailsweylsgg   
181 ssipeghcya effynwyfli tastlefftp flsvtffnls iylniqrrtr lrldgareaa    
241 gpepppeaqp spppppgcwg cwqkghgeam plhrygvgea avgaeageat    
lgggggggsv   
301  asptsssgss srgterprsl krgskpsass aslekrmkmv sqsftqrfrl srdrkvaksl 
361  avivsifglc wapytllmii raachghcvp dywyetsfwl lwansavnpv lyplchhsfr 
421  raftkllcpq klkiqphssl ehcwk paaprgalrg rahsrgapsr rrprprwrsa 
 
Figure 2 The amino acid sequences of the full length human H3R and its isoforms and 
the peptide sequences used to generate specific antibodies to those isoforms. (A) H3R 
amino acid coding sequence, (B) H3R445 amino acid sequence and selected 
immunogen sequence. (C) H3R365 amino acid sequence with the area spliced out 
highlighted in red and selected immunogen sequence in blue. (D) H3R365 amino acid 
sequence with the area spliced out highlighted in red and selected immunogen 
sequence in blue. H3R329 amino acid sequence with the area spliced out highlighted in 
red and selected immunogen sequence in blue. H3R200 amino acid sequence with the 
area spliced out highlighted in red and sequence highlighted to raise an antibody 
against selected immunogen sequence in blue. 
 
Methods 
Choice of Peptide Sequences      
Specific peptide sequences were chosen to immunize rabbits to produce anti-peptide 
antibodies (Figure 2). The peptide was chosen based on the peptide specificity being 
unique to the particular isoform and its likely immunogenicity using the rationale 
described herein and previously (10). A cysteine residue was added to one end of each 
sequence so that the peptide could be directionally coupled to a carrier protein, keyhole 
limpet hemocyanin (KLH) or thyroglobulin to ensure the appropriate configuration of 
peptide was maintained: 
 
Figure 3 Anti-human H3R isoform Antibody Panel  
Ab 1 was generated against a sequence specific to the i3 region in the rat H3C isoform 
rH3C (268 – 277) EAMPLHRGSK-Cys 
Human H3R isoform specific antibodies: 
Ab 2 Human H3R (365) peptide 1   (268 – 281)   EAMPLHRKVAKSLA-Cys 
Ab 3 Human H3R (365) peptide 2    (268 – 278)  Cys-EAMPLHRKVAK 
Ab 4 Human H3R (329) ΔI3             (222 – 231)     Cys-YLNIQSFTQR 
Ab 5 human H3R (200)              (191 – 200)  Cys-RRPRPRWRSA 
8 
 
8 
 
 
Antibody Production        
The 10-15-mer peptide alone is too small to stimulate an adequate immune response 
and is therefore conjugated to a large immunogenic carrier protein before being 
injected into the rabbit (female Dutch and NZ white rabbits are commonly used 
breeds). The peptide is conjugated using Imject® Maleimide activated mcKLH kit to 
illicit an enhanced humoral immune response. The rabbit serum is collected and 
purified using peptide affinity chromatography.   
 
The Imject Maleimide activated mcKLH method of coupling peptides to carrier 
proteins 
The method was used to conjugate the peptide to the carrier protein KLH through its 
carboxyl-terminal cysteine residue. There are other coupling strategies available, 
including Amino- and Carboxy-terminal coupling described in other publications (10). 
 
1. Dissove one vial of maleimide-activated mcKLH by adding 200 µl of distilled 
water, making a 10 mg/ml solution. 200 µl of conjugation buffer was added to 
5 mg synthetic peptide (Note 1).  
2. Imediately add the peptide solution to the reconstituted mcKLH. Incubate the 
carrier protein and peptide mixture for a further 2 hours at room temperature 
with gentle agitation.  
3. Separate the conjugated peptide from EDTA by desalting. Dissolve one bottle 
of purification buffer salts in 60 ml of distilled water. Remove the top and bottom 
caps from a desalting column and wash 3 times with 15 ml of purification buffer 
salts. Add the hapten-carrier mixture to the centre of the column disc. Apply to 
the column and collect each of the fractions sequentially.  
4. Read the absorbency of each fraction at 280 nm to detect the fractions 
containing the conjugate. Pool the peak fractions, and re-read the absorbence. 
Dilute the peptide protein conjugate with PBS to a final concentration of 1 mg/ml 
and store in 100 µl aliquots at -20oC. 
 
Note 1: Synthetic peptides can be purchased commercially from various 
companies (eg. Cambridge Research Biochemical, Billingham, UK), at >98% 
purity is sufficient. Ideally at least 15 mg are required for all procedures. 
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Inoculation Procedure 
1. Carefully mix 200 µl of sterile PBS with 100 µg of freshly thawed peptide-carrier 
protein conjugate, and emulsify with an equal volume of Freund’s adjuvant 
(Sigma, UK)  using a 1 ml syringe (Note 2).  
2. All procedures are performed in accordance with the UK Animals Scientific 
Procedures Act 1986, or equivalent. 
3. Inject the Conjugate-Adjuvant preparation equally using a 25-gauge needle 
intramuscularly into both hind legs of a Dutch or New Zealand White rabbit 
(Note 3). Perform the primary immunisation using complete Freund’s adjuvant, 
while for subsequent immunisations (at 1 month intervals) use Freund’s 
incomplete adjuvant.  
4. Bleed rabbits (See Note 3) from the marginal ear vein 7 – 10 days following the 
booster injections, and collect 10 – 15 ml of blood. Allow blood to stand at room 
temperature for 2 hours, and then for 16 hours at 4oC to complete clot formation 
and contraction, respectively.  
5. Remove cellular material by centrifugation at 12000 x g for 10 minutes at 4oC, 
and store the serum in 1 ml aliquots at -20oC.  
 
Note 2: Complete emulsification is very important for a successful protocol. 
Routinely, this is checked by leaving the sample to stand for at least 30 minutes 
at room temperature and ensuring that the adjuvant and conjugate do not 
separate into two layers. If this occurs further mixing is required and should be 
retested prior to inoculation. 
 
Note 3: In order to ensure that both inoculation and bleeding procedures are 
stress-free, rabbits are withstrained gently by an experienced handler in a 
dedicated clean lab coat with holes cut out for ears to protrude, and back legs 
supported to ensure the animals do not injure themselves. Rabbits are routinely 
housed in small groups in large cages or free-range, the latter being more stress-
free. 
 
In order to improve the quality and specificity of the antibodies, purification is 
recommended, particularly for use in immunohistochemical and quantitative 
immunoblotting experiments. 
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Affinity Purification 
 
Coupling of Peptides to Sepharose Beads  
The method is carried out largely as described by Chazot et al., 1999 and is used to 
couple the peptide to activated thiol-sepharose beads via its C-terminal cysteine 
residue.  
 
1. Allow 0.35g of activated thiol-sepharose to swell in 100 ml distilled water for 15 
minutes at room temperature. Place the swollen sepharose beads in a 25 ml 
column containing a scinter filter and wash with 100 ml of 0.1 M Tris-HCL pH 
8.0, containing 0.3 M NaCl and 1mM EDTA.  
2. Drain the column until 0.7 ml of buffer remained. Dissolve 1 ml of 5 mg/ml 
peptide in the 0.1 M Tris-HCL pH 8.0, containing 0.3 M NaCl and 1mM 
EDTAand add to the swollen sepharose beads and incubate for 2 hours at room 
temperature with gentle agitation.  
3. Terminate the reaction by draining the column and washing the sepharose 
beads with 25 ml of Tris pH 8.0 followed by 10 ml of 0.1 M citric acid pH 4.5. 
All remaining un-reacted thiol groups on the sepharose beads are blocked by 
incubation with 3 ml of 1 mM β-mercaptoethanol in 0.1 M citric acid pH 4.5 for 
1 hour at room temperature with gentle agitation.  
4. Terminate the blocking reaction by washing the sepharose beads with 25 ml of 
0.1 M citric acid pH 4.5. Finally equilibrate the sepharose column with 25 ml 
PBS and store in 10 ml PBS containing 0.02% (w/v) sodium azide, at 4oC until 
required.      
 
Peptide Affinity Purification of Antibodies 
Purification of the anti-peptide polyclonal antibody requires the use of a 1 ml sepharose 
column linked to the appropriate peptide (5 mg) as described above.  
1. Equilibrate the column with 100 ml of PBS, and drain. Then apply 4 ml of the 
immune serum to the column followed by either a 2 hour incubation period at 
room temperature or overnight at 4oC with gentle agitation.  
2. Drain unbound immune serum from the column (Note 4), and then wash the 
column slowly with 100 ml of PBS. Elute the bound antibody from the column 
with 8 ml of 50 mM glycine/HCL pH 2.3. Collect the eluate in 8 X 1 ml fractions, 
containing 15 µl of 1 M Tris to neutralise the contents to a final pH of approx. 
7.4. For each fraction determine the O.D. at λ = 280 nm using standard 
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spectrophotometer, and pool the peak fractions (at least 0.1 OD unit); The 
protein concentration can be calculated using the Beer Lambert law, 
C =  A / ЄL 
Where,   
C, is the protein concentration of the antibody 
A, is the absorbance at λ = 280 nm 
L, is the sample path length = 1 cm. 
Є, is the molar absorptivity or extinction coefficient of the chromophore at wavelength 
λ (the optical density of a 1 cm thick sample of a 1 M solution). Є is a property of the 
material and the solvent = 1.35 
 
3. Pool the fractions containing the highest protein concentrations and dialyse 
with strirring against 500 ml TBS or PBS, overnight at 4oC.  
4. Regenerate the affinity column with 100 ml of TBS and store in 10 ml TBS 
containing 0.02% (w/v) sodium azide at 4oC. Affinity columns can be kept for 
many years without losing their ability to purify antibodies. 
 
Note 4: Retain the unbound fraction and store in case the affinity column is 
overloaded and does not retain all the available antibody. This is rare but does 
happen occasionally. 
 
Validation Methods 
Transfection methods for individual H3R isoform expression studies 
Cell culture and transfection of Human Embryonic Kidney (HEK) 293 cells 
Preparation of DMEM/F12 media   
All procedures should be performed under sterile conditions.  
 
1. Mix powdered Dulbecco’s Modified Eagle Medium/F12 (DMEM/F12 1:1 ratio) 
(15g/L) and 15mM N-2-hydroxyethylpoiperazine-N’-2-ethane sulphonic acid 
(HEPES) with 800 ml of sterile water. Supplement the media with 40 ml of 10% 
(v/v) foetal calf serum (FCS), 7.5 % (w/v) NaHCO3 giving a final concentration 
3.0g/L, and 20 ml of penicillin (500 µg/ml)/ streptomycin (500 µg/ml) solution. 
2. Adjust the pH of the media to pH 7.6 using 10M NaOH and the final volume 
made up to 1 L using sterile ddH2O. Filter-sterilise the media using a 0.2 µm 
Sartorius Satolab-V150 filter unit, and then store at 4oC.  
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Sub-culturing of HEK 293 Cells 
Perform all procedures under sterile conditions.  
HEK 293 cells are grown in 250 ml Greiner flasks containing DMEM/F12 (as described 
above). The flasks are incubated in a Sanyo incubator at 37oC, humidified in 5% CO2. 
Every seven days the cells are sub-cultured.  
1. 30 minutes before, prewarm sterile PBS, DMEM/F12 media and trypsin-EDTA 
to 37oC.  
2. Remove the old medium from the cells and wash the cells in 10 ml of pre-
warmed PBS.  
3. Remove the PBS and incubate the cells for 2 min in 2ml of trypsin-EDTA, at 
37oC.  
4. Re-suspend the cells in 10 ml of fresh pre-warmed DMEM/F12 media by gentle 
pipetting up and down.  
5. Add 2 ml of the cell suspension to a fresh sterile flask with a further 10 ml of 
fresh media and return back to the CO2 incubator.   
 
Polyethyleneimine (PEI) transfection method 
Mammalian cells can be transfected efficiently (up to 30%) using several different 
techniques, including calcium precipitation, and methods using polyethyleneimine or 
lipofectamine (the former two being relatively inexpensive if finances are tight). Herein 
the polyethyleneimine (PEI) method for the transfection of HEK 293 cells adapted from 
(11), for a 3 ml petri dish of cells (approx. 80% confluent) is described.  
1. Dilute 1 µg cDNA (pCIS Flag-tagged hH3R isoform, Note 5) in 100 µl 0.9% 
NaCl in a 1.5ml eppendorf, then add 2 µl of 1 mg/ml PEI (linear MW ~ 25,000) 
and flick gently to mix the contents.  
2. Incubate the cDNA/PEI mixture freestanding for 10 minutes at room 
temperature. During the incubation period, remove the old media from the HEK 
293 cells and add 2 ml of fresh pre-warmed media.  
3. Following the incubation period, add the 1 ug DNA/PEI mixture to the HEK 293 
cells gently mix and incubate at 37oC in a standard CO2 incubator. 
 
Note 5: This CMV promoter cDNA construct Ideal for expression in mammalian 
cells) was a kind gift from (5), epitope tagged with a FLAG sequence which offers 
an alternative method of detection using commercial anti-FLAG antibodies 
(Sigma, UK) 
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Harvesting cells and membrane preparation of HEK 293 cells 
1. 48 hours post transfection, remove/aspirate the culture media and replace with 
1 ml of homogenisation buffer.  
2. Scrape cells from the bottom of the petri dish using a Greiner cell scraper. 
Homogenise the re-suspended cells using a dounce glass/glass homogeniser, 
kept ice cold. 
3. Pellet the homogenate by centrifugation at 18000 x g at 4oC for 5 minutes.  
4. Discard the supernatant and re-suspend the pellet in 1 ml of ice cold 
homogenisation buffer.  
5. Re-homogenise the membranes and divide in 100 µl aliquots and store at -
20oC.  
 
Immunoblots 
One of the standard methods to utilise the antibodies is immunoblotting. Sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is commonly 
carried out using either 7.5 (v/v) or 10% (v/v) polyacrylamide slab gels (appropriate for 
analysing monomeric (30-45kDa) and dimeric species (75-90kDa)) under reducing 
conditions. Lower percentage polyacrylamide can be used for higher molecular weight 
proteins. Immunoblots can then be probed either with either anti-FLAG antibody 
(commercial, Sigma) in the case of the FLAG tagged human H3R clones, or with the 
appropriate rabbit anti-H3R antibodies (untagged human H3R clones).  
 
Preparation of resolving gel 
1. Recipe for Resolving gel is as follows:  
2. Prepare the resolving gel by mixing 6 ml of double-distilled water with 3 ml of 
resolving gel buffer (50 mM Tris, 384 mM glycine, 1.8 mM EDTA and 0.1% 
(w/v) SDS pH 8.8), 6 µl of TEMED, 3 ml of stock 30% acrylamide, and 60 µl 
10% (w/v) ammonium persulphate (APS). Immediately pour the polyacrylamide 
solution gently into a pre-assembled Hoefer SE 245 dual gel caster, using two 
gel plates of 10 x 8cm and spacers of 1 mm width.  
3. Layer 100 µl of saturated water/ butanol solution over the top of each gel. Cover 
the gels with parafilm and allow to polymerise for 40 - 60 minutes at room 
temperature. The gels can be used immediately or stored by wrapping the gels 
individually in tissue paper and stored in electrode buffer (50 mM Tris, 384 mM 
glycine, 1.8 mM EDTA and 0.1% (w/v) SDS pH 8.8.) at 4oC until required.   
 
 
14 
 
14 
 
Preparation of protein samples for SDS-PAGE 
Protein samples for SDS-PAGE are precipitated using the chloroform/ methanol 
precipitation.  
 
1. To the protein sample (25-50 µg), add 4 x volumes of ice-cold methanol and 
vortex-mix samples and centrifuge at room temperature at 18,000 x g for 1 
minute.  
2. Add 1 x volume of ice-cold chloroform to the samples, vortex-mix and centrifuge 
at room temperature at 18,000 x g for 1 minute.  
3. Add 3 x volumes of ice-cold water to the samples, vortex mix and centrifuge at 
room temperature at 18,000 x g for 1 minute.  
4. Carefully discard the upper layer and add 1x volume ice-cold methanol to the 
samples, vortex-mix and centrifuge at room temperature at 18,000 x g for 4 
minute.  
5. Discard the supernatant and ari-dry the pellet. Re-suspend the dried protein 
pellet by vortex mixing in 5 µl of sample buffer (30 mM sodium hydrogen 
phosphate, pH 7.0, 30% (v/v) glycerol, 0.05% (v/v) bromophenol blue and 7.5% 
(w/v) SDS), 2 µl of 200mM DTT and 8 µl of water to a final volume of 15 µl.  
6. Boil the samples at 95oC in the heat block for 5 minutes and then centrifuge at 
18,000 x g for 30 seconds at room temperature before analysis by SDS-PAGE. 
 
SDS-PAGE 
1. Carefully clamp the resolving mini-slab acrylamide gel into a Hoefer mini-
vertical gel electrophoresis unit SE260.  
2. Prepare the stacking gel by mixing 2.3 ml of water with 1 ml of stacking gel 
buffer (0.5 M Tris-glycine, pH 6.8, containing 8 mM EDTA and 0.4% (w/v) SDS), 
650 μl of stock 30% acrylamide, 5 μl of TEMED and 80 μl of 10% (w/v) 
ammonium persulphate.  
3. Pour the stacking gel mixture immediately and gently (avoiding air bubbles) into 
the mini-slab gel on top of the resolving gel and insert a welled comb into the 
stacking gel. Polymersation takes up to 10 minutes.  
4. Check and carefully remove the comb and wash the the wells with double-
distilled water.  
5. Pour approximately 300 ml of electrode buffer (see above) into and behind the 
wells and into the base of the electrophoresis unit.  
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6. Load using a Hamilton syringe or pipette with gel loading tip extansion 15 μl of 
Protein samples and pre-stained standards (protein molecular weight range of 
200 – 6.5 kDa) into the ten wells of the stacking gel.Ensure all lanes are loaded. 
7. Perform electrophoresis at a constant current (10 mA (per gel) initially and then 
increase the current by 5 mA or 10mA (per gel) once the samples reached the 
resolving gel. Gel run time is approximately 2 hours or until the appropriate pre-
stained molecular weight marker (25 kDa) are at the bottom of the resolving 
gel.   
 
Immunoblotting stage 
After SDS-PAGE is complete, the proteins from the gels are transferred to a 
nitrocellulose membrane. 
1. Recipe for Transfer buffer is as follows: 25 mM Tris, pH 8.4, 192 mM glycine 
and 20% (v/v) methanol. 
2. In order to do this, construct a transfer cassette in the following order of 
components each of which had been pre-equilibrated in transfer buffer sponge, 
two sheets of blotting paper, nitrocellulose membrane, SDS-PAGE gel, two 
sheets of blotting paper and finally a piece of sponge.  
3. On the addition of each component to the transfer cassette, remove air bubbles 
carefully using a glass pipette or plastic tube. Transfer proteins at a constant 
voltage of 50 V for 2 hours using a Hoefer TE 22 tank transfer unit containing 
transfer buffer kept cool with external ice packs.  
4. Following the transfer of the proteins, briefly rinse the nitrocellulose and 
incubate with 15 ml of blocking buffer, which comprises of PBS, containing 5% 
(w/v) dried milk and 0.02% (v/v) Tween-20, for 1 hour at room temperature with 
gentle agitation.  
5. After blocking of the non-specific antibody sites, wash the nitrocellulose 
membrane with 10 ml of PBS. Dilute the appropriate affinity-purified primary 
antibodies in incubation buffer, which comprises of PBS, containing 2.5% (w/v) 
dried milk to working concentrations of (0.25 – 5 µg purified antibody/ml). 
6. Incubate the nitrocellulose membranes with 10 ml of the diluted primary 
antibody solution for 2 hours at room temperature, or overnight at 4oC with 
gentle agitation (petri dish or plate). 
7. After incubation with the primary antibody, wash the nitrocellulose membranes 
four occasions in 10 ml of wash buffer, consisting of PBS, containing 2.5% (w/v) 
dried milk and 0.2% (v/v) Tween-20, for 10 minute intervals with gentle agitation 
on a shaker at room temperature.  
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8. Incubate the nitrocellulose membranes for 1 hour with gentle agitation with 
horseradish peroxidise (HRP) labelled secondary antibody, either anti-rabbit or 
anti-mouse depending on the host species for primary antibody, at a dilution of 
1/2000 in 10 ml of incubation buffer.  
9. Remove the unbound secondary antibody by washing the membrane as 
detailed above. 
10. Drain the nitrocellulose and briefly rinse with PBS 
11. Develop the immunoreactive bands on the nitrocellulose membrane by 
processing in a solution containing, 100 μl of 68mM p-coumaric acid, 10 ml of 
1.25 mM luminal and 6 μl of 30% (v/v) H2O2, for 1 minute at room temperature 
(note 6).  
12. After incubation, wrap the immunoblot in cling film, and place in a film cassette. 
13. Expose the immunoblots to HyperfilmTM for various times between 1-5 minutes, 
and develop the film developed in Kodak D-19 Developer until the 
immunoreactive bands are visible and fix in Kodak Unifix for 5 minutes at room 
temperature.  
 
Note 6: This is a homemade recipe developed in the laboratory. It has a drawback 
in that it lacks a stabiliser and has a use limit of aprox. 10 minutes. There are a 
number of commercial products which can be used which contain stabilisers 
and can be utilised for longer. 
 
Immunohistochemical analysis 
Immunohistochemical analysis is carried out as essentially described previously by 
Chazot et al. (2001); Cannon et al. (2007). 
 
Diaminobenzidine IHC 
1. Perfusion-fix adult mouse brains with 4% (w/v) paraformaldehyde (0.05% (v/v) 
glutaraldehyde in 0.1M phosphate buffer, pH 7.4.  
2. Remove brains, post-fixin 4% (w/v) paraformaldehyde (0.05% (v/v) 
glutaraldehyde in 0.1M phosphate buffer, pH 7.4overnight and then cryoprotect 
the tissue by incubation in 10%, 20% and 30% (w/v) sucrose in 0.01 M 
phosphate buffer, pH 7.4 at 4oC for 48 hours in an even step-wise-manner. 
3. Freeze the tissue at -80oC in isopentane for 1.5 minutes, and cut coronal 
sections (25 µm thick) on a cryostat set to -20 oC. Pick up sections using a fine 
paintbrush and store in PBS (with 0.05% sodium azide) for no more than 2 
weeks at 4 oC. 
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4. Treat free-floating sections initially with 10% (v/v) methanol and 3% (v/v) 
hydrogen peroxide in 50 mM TBS, pH7.4, for 10 minutes to quench 
endogenous peroxidise activity.  
5. Incubate sections in PBS, 0.2% (w/v) glycine and 0.2% (v/v) Tween-20, for 15 
minutes to mop up residual un-reacted aldehyde groups from the fixative.  
6. Block non-specific antibody binding sites on the tissue by incubating with 2% 
(v/v) foetal calf serum in PBS, 0.02% (v/v) Tween-20 for 1 hour. S 
7. Incubate sections overnight at 4oC in the primary anti-H3R antibody at a range 
of concentrations (0 – 5 µg/ml) in 1% (v/v) foetal calf serum/ PBS.  
8. After washing the sections on threeoccasions in PBS/ 0.1% (v/v) Triton X 100, 
detect antibody binding using the Vectastain ABC Elite kit.  
9. Incubate the sections with a biotin linked, anti-rabbit secondary antibody for 2 
hours followed by incubation for 1 hour with streptavidin-horse radish 
peroxidase (HRP) complex.  
10. Visualise the immune reaction using 3,3’-diaminobenzidine tetrahydrochloride 
as the HRP substrate. 
 
Immunofluorescence protocol 
1. Perfuse-fix adult mouse brains with 4% (w/v) paraformaldehydein 0.1M 
phosphate buffer, pH 7.4.  
2. Remove brains, post-fixin 4% (w/v) paraformaldehyde in 0.1M phosphate 
buffer, pH 7.4overnight and then cryoprotect the tissue by incubation in 10%, 
20% and 30% (w/v) sucrose in 0.01 M phosphate buffer, pH 7.4 at 4oC for 48 
hours in an even step-wise-manner. 
3. Freeze the tissue at -80oC in isopentane for 1.5 minutes, and cut coronal (or 
other appropriate orientation) sections (14 µm thick) on a cryostat set to -20 
oC.Free floating sections may be collected as above, alternatively if thinner 
sections are preferred (8-16 µm), they can be collected onto poly-L-lysine 
coated slides, air dried and stored at -80oC in air tight boxes until use. 
4. On the day of the assay remove the slides from the freezer and air dry again 
for one hour. 
5. Block the sections for 45 mins at room temperature in PBS pH 7.4 containing 
0.4% Triton X-100, 4% foetal calf serum (FCS) or normal serum from the same 
species as the secondary antibodies are raised in and 1% bovine serum 
albumin (BSA). 
6. Following the blocking stage rinse the sections briefly in PBS and thenincubate 
for 48 hrs at 4oC with primary anti-H3R antibody at a range of concentrations (0 
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– 5 µg/ml).The antibody diluent for both the primary and secondary antibodies 
is PBS pH 7.4 containing 0.1% Triton X-100, 1% FCS (or normal serum as 
before) and 1% BSA. 
7. Rinse sections and wash in PBS (3 x 10 mins), and then apply secondary 
antibodies:fluorophore linked anti-rabbit antibodies e.g. Cy3 or Alexa 488, for 1 
hour. 
8. Rinse sections and wash in PBS as before and mount in Citifluor AF4 or 
equivalent. 
 
Controls should include the omission of the primary antibody and a peptide block 
where the primary antibody is pre-incubated with the relevant peptide immunogen 
(100-fold excess) to confirm antibody specificity. 
 
Peptide block to confirm antibody specificity for individual immunogen 
In order to confirm that immunoreactivity detected either in the immunoblots or in 
immunohistochemical analysis is specific to the amino acid sequence of the 
immunizing peptide, a peptide block can be carried out. 
1.  Pre-incubate the antibody overnight at 4oC with an equal volume of the 
relevant peptide. The peptide is used in excess (500 µg/ml) to ensure complete 
blockade of antibody binding. 
2. Adjust the final antibody dilution to take into account the initial 1:2 dilution with 
the peptide.  
Any immunoreactive bands or staining which persists after the antibody block is 
considered to be due to non-specific antibody binding. Anti-human H3R isoform specific 
antibodies have been validated against HEK 293 cells transfected with the respective 
H3R isoform cDNA. The next set of results looks at the validation of each of the 
antibodies. 
 
Representative examples of results for specificity demonstration and control 
experiments 
 
Isoform specificity of the anti-rH3A/C/ hH3R445/453(268-277) antibody 
The sequence chosen is specific to third intracellular loop region of the rat H3C isoform. 
The antibody is shown to be selective for the rat H3A, rat H3C, but not rat H3B (not 
shown). Herein, it is shown that the antibody in terms of human isoform also detects 
both the full length human H3R445and H3R453isoforms (Figure 4). The H3R453 isoform is 
the result of an additional exon utilised resulting in an additional 8 amino acids added 
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at the C-terminus (Wellendorph et al., 2002). The significance of this very rare isoform 
is yet to be determined. 
 
Immunoblot showing labelling of the human H3R445/ 453 isoforms using the anti-
rH3RAC / hH3R 445/453 antibody: 
Ab 1. Isoform specificity of the rH3C (268 – 277) antibody  
rH3C (268 – 277) EAMPLHRGSK-Cys 
Sequence specific to the i3 region in the rat H3C isoform. This antibody was shown to 
be selective for the rat H3A and rat H3C isoforms and, surprisingly only the full length 
human H3(445/453) isoform (Fig 4). Antibodies purified from this sequence in different 
rabbits and different bleeds consistently showed the same human H3 (445) selectivity 
(13) 
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Figure 4 (A) Immunoblot of five different human H3R isoforms probed with anti-rH3AC/ 
hH3R445/453 specific antibody. 
Approximately 25 µg of protein/ well were loaded onto a 7.5% PAGE gel. Once 
transferred the membrane was probed with affinity purified anti-rH3AC/ hH3R445/453 
antibody (1 µg/ml concentration). The antibody detects only the full length hH3R 445 
and 453 isoforms with no cross reactivity with the shorter isoforms. The lower panel 
shows the corresponding β-actin, probed with monoclonal mouse anti β-actin antibody 
(1:5000). Lane 1, HEK 293 cells untransfected but still contain PEI; Lane 2, HEK 293 
cells expressing hH3R200; Lane 3, HEK 293 cells expressing hH3R329; Lane 4, HEK 293 
cells expressing hH3R365; Lane 5, HEK 293 cells expressing hH3R453; Lane 6, HEK 293 
cells expressing hH3R445.  
 
Figure 4 (B) Immunoblot of three different FLAG tagged human H3R isoforms probed 
with anti-FLAG (lanes 1-3) and the anti-rH3AC/ hH3R445/453 specific antibody (lanes 4-7). 
Homogenates of HEK 293 cells transfected with three different human H3R isoforms 
(329, 365 and 445), all epitope tagged with FLAG were prepared. Approximately 25 µg 
of protein/ well were loaded onto a 7.5% PAGE gel. Identical sample were run on both 
left and right hand sides of the gel. Once transferred onto a nitrocellulose membrane, 
the left side panel was probed with a monoclonal mouse anti-FLAG antibody (1:5000 
dilution) while the right side panel probed with affinity purified anti-rH3AC/ hH3R445/453 
antibody (1 µg/ml concentration). The FLAG antibody reacts with all three isoforms 
with monomeric species migrating at approximately Mr 33, 36, 44 kDa. The anti-rH3AC/ 
hH3R445/453 antibody detects only the full length 445 isoform with no cross reactivity with 
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the two shorter isoforms. Lower panel shows corresponding β-actin signal, probed with 
monoclonal mouse anti β-actin antibody (1:5000). Lanes 1 and 5, HEK 293 cells 
expressing hH3R329; Lanes  2 and 6, HEK 293 cells expressing hH3R365; Lanes 3 and 
7, HEK 293 cells expressing hH3R445; Lanes 4, HEK 293 cells untransfected but still 
contain PEI. All blots shown are representative blots from at least 8 similar 
experiments.  
 
Once the reactivity of antibody against the human H3R isoform transfected cells was 
determined, the selectivity of the antibody was determined (Fig 5). 
 
 
 Figure 5: Selectivity of the anti-rH3AC/ hH3R445/453 antibody using the 
corresponding peptide sequence: 
Immunoblot confirming the selectivity of the anti-rH3AC / hH3R445/453 antibody. 
Approximately 25 µg of protein/ well were loaded onto a 7.5% PAGE gel. Identical 
samples were run on both left and right hand sides of the gel. Once transferred onto a 
nitrocellulose membrane, the left side was probed with the affinity purified anti-rH3AC/ 
hH3R445/453 antibody (1µg/ml concentration) while the right side was probed with affinity 
purified anti-rH3AC/ hH3R445/453 antibody pre-incubated with the antigen peptide (1 µg/ml 
concentration).  
 
The major immunoreactive bands labelled in HEK 293 expressing the hH3R453 or hH3R 
445 (lanes 1 and 2, respectively) were greatly suppressed by pre-incubation with the 
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antigen peptide (lanes 4 and 5), demonstrating the sequence selectivity of the 
antibody. Lane 3, HEK 293 cells mock transfected. Lower panel shows corresponding 
β-actin, probed with monoclonal mouse anti β-actin antibody (1:5000). The anti-rH3RAC/ 
hH3R445/453 antibody has been shown to detect only the full length human and rat 
isoforms as well as a truncated rH3RC isoform. This antibody is useful for looking at the 
full length H3R in both rodent and human tissue.  
 
Occasionally, this rationale directed approach yields unexpected results. One such 
example is the following antibody where an attempt was made to generate a anti-
hH3R365 selective antibody. However, when screened it was found to only selectively 
identify the hH3R445 isoform. 
 
Isoform specificity of the anti-hH3R365 peptide 2 (268-278) antibody 
The sequence chosen is specific to the third intracellular region in the human H3R365 
isoform. This antibody was shown to be selective for the human H3R445 isoform only 
(Figure 6). 
 
 
 
 
Figure 6 Immunoblot of five different human H3R isoforms probed with anti-
hH3R365 peptide 2 specific antibody. 
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Approximately 25 µg of protein/ well were loaded onto a 7.5% PAGE gel. Once 
transferred the membrane was probed with affinity purified anti-hH3R329 antibody (3 
µg/ml concentration). The anti-hH3R329 antibody detects only the H3R 329 isoform. No 
cross reactivity with the other shorter or longer isoforms was detected. Lower panel 
shows the corresponding β-actin, probed with monoclonal mouse anti β-actin antibody 
(1:5000). Lane 1, HEK 293 cells mock transfected; Lane 2, HEK 293 cells expressing 
hH3R200; Lane 3, HEK 293 cells expressing hH3R329; Lane 4, HEK 293 cells expressing 
hH3R365; Lane 5, HEK 293 cells expressing hH3R445; Lane 6,HEK 293 cells expressing 
hH3R453. 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
In contrast, the following antibody was found to selectively label the isoform to which it 
was directed, namely the hH3R329 isoform (Figure 7).   
 
 
 
 
Figure 7 Immunoblot of five different human H3R isoforms probed with anti-
hH3R329 specific antibody. 
Approximately 25 µg of protein/ well were loaded onto a 7.5% PAGE gel. Once 
transferred the membrane was probed with affinity purified anti-hH3R329 antibody (3 
µg/ml concentration). The anti-hH3R329 antibody detects only the H3R 329 isoform. No 
cross reactivity with the other shorter or longer isoforms was detected. Lower panel 
shows the corresponding β-actin, probed with monoclonal mouse anti β-actin antibody 
(1:5000). Lane 1, HEK 293 cells mock transfected; Lane 2, HEK 293 cells expressing 
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hH3R200; Lane 3, HEK 293 cells expressing hH3R329; Lane 4, HEK 293 cells expressing 
hH3R365; Lane 5, HEK 293 cells expressing hH3R445; Lane 6,HEK 293 cells expressing 
hH3R453. 
 
Isoform specificity of the H3R200/ isoform 5 (191-200) antibody 
The sequence was generated to the C terminus of the human H3R200 because of its 
unique C terminal sequence. The antibody was shown to detect immunoreactivity in 
both human putamen (not shown) and recombinant HEK 293 cells expressing the 
H3R200 cDNA (Fig 8).   
 
 
 
Figure 8 Immunoblot of five different human H3R isoforms probed with anti-
hH3R200 specific antibody. 
Approximately 25 µg of protein/ well were loaded onto a 10% PAGE gel. Once 
transferred the membrane was probed with affinity purified anti-hH3R200 antibody (3 
µg/ml concentration). The anti-hH3R200 antibody detects only the 200 isoform. No cross 
reactivity with the longer isoforms was detected. Lower panel shows the corresponding 
β-actin, probed with monoclonal mouse anti β-actin antibody (1:5000). Lane 1, HEK 
293 cells mock transfected; Lane 2, HEK 293 cells expressing hH3R200; Lane 3, HEK 
293 cells expressing hH3R329; Lane 4, HEK 293 cells expressing hH3R365; Lane 5, HEK 
293 cells expressing hH3R445; Lane 6, HEK 293 cells expressing hH3R453. 
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Validation studies using H3R KO mice 
 
Immunoblotting (IB) studies in mice 
As a representative, the specificity of the anti-rH3A/C/ anti-hH3(445) antibody for murine 
H3Rs was confirmed by using it to probe immunoblots of (H3R +/+) wild type (WT) and 
(H3R -/-) knockout (KO) mouse brain.  Two bands at Mr 50,000 (+ 2000) and Mr 44,000 
(+ 2000) were consistently detected in WT mouse brain but not in the KO material. 
Occasionally a Mr 40,000 species was also selectively detected (Figure 9). 
 
Fig 9 Immunoblot using anti-rH3A/C/ anti-hH3 (445) to compare H3 receptor 
immunoreactivity in H3R -/- knockout (KO) mice with H3R +/+ wild type (WT) mice 
KO and WT mouse forebrain (10 µg protein) was probed in parallel with anti-rH3A/C/ 
hH3 (445) R used at 1µg/ml. Two bands at Mr 50,000 + 2000 and 44,000 + 2000 were 
consistently detected in WT but not in KO material (n = 3 separate mice). After each 
immunoblot the nitrocellulose sheet was stained with Ponceau S to confirm that the 
total protein loading was the same for both the KO and WT lanes.  
 
Immunohistochemical (IHC) studies in the mouse 
Immunohistochemical studies using anti-rH3A/C/ anti-hH3(445) antibody to compare 
immunoreactivity in H3R -/- (KO) mice with wild type (WT) mice clearly demonstrated 
the specificity of this antibody. The anti-rH3A/C/hH3(445) isoform specific antibody was 
used to carry out a detailed mapping of the anatomical distribution of the H3R in mouse 
brain. IHC was carried out in wild type (H3R +/+) mouse brain slices alongside identical 
slices obtained from (H3R -/-) animals. Additional controls included the prior incubation 
of the anti-hH3 (445) antibody with its respective peptide such that specific 
immunoreactivity would be blocked. To achieve this, the primary antibody was 
incubated with the peptide at a final concentration of 500µg/ml overnight at 4oC. Before 
use the antibody/peptide mixture was diluted such that the final antibody concentration 
50 kDa
44 kDa
40 kDa
KO    WT KO   WT KO   WT
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was the same as for the unblocked antibody. As a second control IHC was carried out 
with the secondary antibody alone. 
 
A descriptive summary of the immunoreactivity in selected brain regions is shown in 
Table 1 for both wild type and H3R -/- mice. Table 1 a) and b) show results using the 
pan anti-H3R (346-358) antibody and the isoform specific anti-rH3A/C/ anti-hH3(445) 
antibody, respectively. The data are from three different mice and the findings are in 
agreement with those from an independent laboratory using our antibodies to screen 
at least four further WT and KO animals (Dr Keri Cannon, Johnson & Johnson). 
Intensity of staining has been graded 0 – 4, with 0 being equivalent to background and 
4 representing intense labelling. The strongest specific staining (that is not present in 
knockout animals) was seen in cortical laminae II, somatosensory cortex, piriform 
cortex, and the amygdaloid complex (Fig 10A). Moderate reactivity was also noted in 
the str terminalis, str: caudate putamen, fimbria of the hippocampus and the cingulum. 
Weak non-specific reactivity was observed in some of the brain structures of knockout 
animals using the anti-rH3A/C/ anti-hH3(445) antibody (Figure 10). This non-specific 
staining was not seen with an immunofluorescence detection system using rhodamine 
linked anti-rabbit secondary antibodies (Fig 10B).  
 
The background strain of the H3R -/- mice is C5731/6J (US Patent no. 7151200). In 
contrast to results using the pan anti-H3 (346 – 358) in B6C3Fe mice (7) there was 
negligible immunostaining in the deeper cortical layers and little detectable signal above 
background in the CA1, CA2 and CA3 regions of the hippocampus. In B6C3Fe mouse 
brain slices pan anti-H3 (346 – 358) immunoreactivity was detected in cortical layers II 
and V, and in the CA3 region of the hippocampus (7). 
 
Table 1 a) Summary of some key mouse brain structures labelled using pan-H3 
receptor antibody 
 
Tissue H3R +/+ H3R -/- 
Striatum +3-4 0 
Sunstantia nigra +3 0 
S1/S2 cortex +3-4 +1 
Cingulate cortex +3 0 
Entorhinal cortex +3 0 
Thalamus +3 0 
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Amygdaloid complex +3-4 0 
Hippocampus CA1 0-1 0-1 
Medial septal cortex 0 0 
 
 
Table 1 b) Summary of some key mouse brain structures labelled using anti- 
rH3A/3C / hH3(445) antibody 
 
Tissue H3R +/+ H3R -/- 
Substantia nigra +4 +1 
Striatum +3 +1 
Cingulum +3 +2 
Somatosensory cortex  +3 0 
Fimbria of the hippocampus +3 +2 
Hippo: CA1/CA2/CA3 0 0 
Cortex layer II +4 0 
Piriform cortex +4 0 
Str terminalis +4 +1 
Amygdaloid complex +4 0 
 
 
 
H3R +/+
 
  
H3R -/- 
 
Somatosensory cortex 
Cortex II 
28 
 
28 
 
 
 
Figure 10A Immunohistochemical detection of H3R immunoreactivity in a range 
of representative brain structures  
 
 
Fig 10B Immunofluorescent detection of H3 immunoreactivity in striatum and 
substantia nigra pars reticulata comparing H3 +/+ (wild type) mice with H3 -/- 
(knockout) mice (Thanks to Dr Keri Cannon) Anti-rH3A/3C /anti-hH3R (445) antibody 
in coronal mouse brain slices. 
 
 
 
Piriform Cortex 
Amygdaloid 
Complex 
 
H3 +/+    H3-/- 
Striatum 
Substantia nigra  
pars reticulata 
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Conclusions 
This chapter describes the development and characterization of a selection of novel 
anti-human H3R isoform selective immounoprobes: These probes can be used to 
investigate expression of three of the human H3R isoforms 445, 365 and 329 in native 
human tissue. Different isoforms have been shown for the first time to be expressed at 
the protein level in the human CNS (eg. 12; 13). Future studies can now explore 
whether there are changes in human H3R isoforms expression in ageing or disease. A 
peptide sequence unique to the rat H3C /H3(397) isoform was chosen and used to 
immunise rabbits for the generation of sequence specific antibodies. The antibody was 
affinity purified and screened against rat and human H3R isoforms expressed in HEK 
293 cells. Immunoblotting of cell homogenates revealed that in addition to detecting 
the rH3C /397 isoform it also labelled the full length 445 isoforms of both the human and 
the rat H3R. The peptide sequence EAMPLHRGSK is found within the third intracellular 
loop of the rat rH3C /397 isoform, aa 268 – 277. The sequence is present in both the 
human and rat full length forms but in the rH3C /397 isoform it is split: EAMPLHR 
appearing on the 5' side of the deletion site and GSK on the 3' side. Presumably the 
tertiary structure of the receptor is such that the two halves are brought together in a 
structural form which the antibody can recognize. One might have expected the 
antibody to react with hH3 (365) (deletion 275-354) and rH3B /413 (deletion 275 – 306) 
since only the last two amino acids are missing from the EAMPLHRGSK sequence in 
these two isoforms. In addition in the full length mouse H3R the sequence is 
EAMPLHRYGV, with the last three amino acids being different from the immunising 
peptide, nevertheless specific anti-H3R immunostaining was detected with both the 
pan anti-H3 and the anti-rH3A/3C /anti-hH3R (445)in mouse brain slices (validated by H3 (-
/-) mice). However, the tertiary structure of the hH3 (365) and rH3B /413 may have been 
unfavourable, with the peptide sequence presumably not accessible to the antibody 
within these isoforms. The hH3(329 ∆IC) (deletion 227 -342) does not possess any of this 
particular peptide sequence and, as expected, no reactivity was seen with this 
expressed clone. 
 
Immunoblots of receptors expressed in HEK293 cells revealed the presence of higher 
molecular weight species in addition to bands running at the expected molecular 
weight of the respective receptor isoforms. The receptor is not being expressed in its 
natural environment and expression levels are generally considerably higher than in 
native tissue. However, higher molecular weight species were also observed in 
immunoblots of native tissue, especially in the human material. Oligomerisation of rat 
H3R has been described by ourselves and others (14,15) and there is a growing 
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consensus that many GPCRs, possibly all of them, function as dimers or higher 
molecular weight oligomers. With rat isoform H3C/397 expressed in HEK 293 cells, 
higher molecular weight species were less apparent than with the full length rH3A/445 
isoform.  
 
Attempts were made to generate antibodies against three more human H3R isoforms 
using an identical strategy. This strategy yielded in some cases unexpected results, 
for example Ab 2 designed to be a selective hH3 365 ab actually yielded a  H3 445/365 
specific antibody, Ab 3 designed to produce a hH3 365 selective antibody surprisingly 
yielded a H3 445 selective antibody. In contrast, Ab 4 designed to produce an anti-H3 
329 antibody, proved successful in yielding such an antibody; Finally, Ab5 directed to 
a unique sequence with the highly truncated H3 200 receptor again proved successful 
despite the limited available selective immunogen sequence. Therefore, to date a 
panel of anti-H3 200, H3 329 and H3 445 antibodies have been successfully generated; 
a mixed specificity H3 365/H3 445 antibody may have some utility in immunoblotting 
methods. 
 
Immunohistochemical (IHC) studies using wild-type and H3R-/- mice (Lovenberg, 
Johnson and Johnson, US Patent no. 7151200) showed a marked ablation in 
immunoreactivity in the knockout animals compared to the wild type, demonstrating the 
specificity of the antibodies. The immunoreactivity in wild type animals was similar for 
both the original pan anti-hH3 (346-358) antibody (not shown) and the new isoform 
selective antibody. The findings also confirmed those of a previous study using the pan 
anti-H3 (346-358) antibody (7) to map the anatomical distribution of the H3R in mouse 
brain slices; with the exception of cortex layer V which showed moderate/strong 
staining in the first study but only light staining in the present investigation, and the 
hippocampus (regions CA1-CA3 and dentate gyrus) where there was some moderate 
reactivity, not found here. It is possible that these differences might be accounted for 
by the fact that different mouse strains were used (B6C3Fe, (7); C5731/6J in the more 
recent study), however further work is necessary to validate these observations and 
confirm their reproducibility. IHC using the anti-rH3C/hH3 (445) antibody demonstrated 
clear specific immunoreactivity in substantia nigra, cortical laminae II, somatosensory 
cortex, piriform cortex, and the amygdaloid complex. Moderate reactivity was also 
noted in the striatum, str terminalis, fimbria of the hippocampus and the cingulum. 
Background labelling was evident in some brain areas in knockout animals, notably the 
fimbria of the hippocampus and cingulum, and to a lesser degree in the striatum; 
nevertheless it was at a significantly lower level than in equivalent areas from wild type 
31 
 
31 
 
mice. This background labelling was not apparent using an immunofluorescent 
detection system e.g. basal ganglia (Fig 10B). A similar picture was observed in the 
pain circuits study with the pan-H3R antibody; clear labelling was observed in wt mice 
for a subpopulation of Aδ fibres, and was completely absent in H3R (-/-) mice; however 
a small subset of Aβ fibres were labelled non-specifically as evidenced by maintenance 
of this immunoreactivity in H3R (-/-) mice (8). Furthermore, in immunoblots comparing 
mouse brain homogenates from WT and KO the animals there was an indication of 
some immunoreactivity in the KO material (8). Care should be taken with screening 
antibodies in KO mice. In the H3R -/- mice, the H3R gene is disrupted by homologous 
recombination (US Patent no. 7151200). A 0.7 kb region covering part of the first intron 
and the 5' end of the second exon is replaced. Although the gene is rendered non-
functional by this disruption with no detectable [3H]-RAMH binding in KO animals (16; 
US Patent no. 7151200) there could possibly be some low level expression of non-
functional H3R protein remaining. This was a significant issue in some of the early H3R 
KO mice. This is also unlikely to be the closely related H4R; EAMPLHRGSK sequence 
is not found within the H4R aa sequence and the anti-rH3C/hH3 (445) antibody does not 
detect recombinant H4R expressed in HEK 293 cells. The high expression in the basal 
ganglia (Fig. 10), particularly in the substantia nigra, is consistent with recent double 
labelling confocal studies using these H3 receptor antibodies.  These have shown that 
the H3 receptor is expressed on subpopulations of GABA-ergic neurons in the sustantia 
nigra and frontal cortex, and furthermore on subpopulations of histaminergic neurons 
in the tubermammilary nucleus, which suggests distinct control of output neurons to 
other brain regions by the H3 receptor (17). 
 
In conclusion, generating Human H3R isoform specific antibodies requires a high level 
of knowledge and expertise. Thorough validation of the antibodies, as described herein, 
is essential before they can be used as reliable probes to investigate the physiological 
relevance of alternative splicing in the human H3 receptor. 
 
Dedication.  
I would like to dedicate this chapter to the memory of my mum for her love and support 
over 5 decades. 
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